We suspect this quarter will ultimately be received poorly by the market given headline margin weakness across the two ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

Once in the small intestines, the higher pH level breaks down the enteric coating ... composition fat versus lean mass loss compared to tirzepatide and dapiglutide in a diet induced obese mouse ...

Once in the small intestines, the higher pH level breaks down the enteric coating ... fat versus lean mass loss, compared to tirzepatide and DAPIglutide in a diet-induced obese mouse mob.

For this purpose, the researchers conducted a retrospective chart review ... changes in lipid levels, blood pressure, and kidney function (measured by estimated glomerular filtration rate) over time ...

The challenge, however, is that Hims & Hers drugs have not been approved by the FDA, which has sued to stop the tirzepatide sales ... The weekly chart shows that the HIMS stock price peaked ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...